← Evidence map

ReviewOncotarget2012

The promise of anti-ErbB3 monoclonals as new cancer therapeutics.

Luigi Aurisicchio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

47 papers cite it

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 22889873